The Series A round, which included participation from North Island Ventures and existing investors, brings New York-based Mural's total funding to $28 million.
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research.
Enterprises are deploying AI agents on top of incomplete and siloed workforce data that sit scattered across HR and finance systems and a decade of point solutions, each with its own definitions and blind spots.
Some of the most interesting moments in music production come when an arrangement won’t work. The groove is there and the melody is promising, but something
Many scientific phenomena are best understood as outcomes of underlying optimization problems, yet automated scientific discovery has largely focused on recovering equations that describe observed input-output patterns. We introduce OptScientist, a novel automated framework for…
Stochastic gradient descent (SGD) is the cornerstone of modern deep learning, yet its theoretical convergence properties remain poorly understood in non-convex settings. To address this gap, we study SGD dynamics in deep linear neural networks - simplified models that retain…
Visual anomaly detection aims to detect abnormal objects, while anomaly samples are often scarce during model training. Assembling multiple pretrained detectors can help by leveraging their transferable image scores and anomaly maps. However, most existing ensemble methods…
Continuous flow language models offer a path to parallel generation with tools for control and acceleration unavailable to discrete diffusion, yet effective techniques for building them at the billion-parameter scale remain less established. We present Lafa (Large flow language…